Car-T: the first agreement for new therapies, based on actual results, is ready. ‘A new negotiation model that puts Italy at the forefront’

Notable that, with payment “for the first bag”, this deal rewards the manufacturer upfront; payment “for the first bag”, however, makes Novartis responsible for manufacturing failures but leaves uncertainty as to who is at risk if manufacturing delays mean that the patient cannot be reinfused.